Latest Price,Fasting C-peptide and insulin were not related to pancreatic cancer

The intricate relationship between proinsulin peptide C and cancer is an emerging area of research, with scientific studies increasingly shedding light on its potential roles in various oncological contexts. While proinsulin and its cleaved component, C-peptide, are primarily known for their function in glucose metabolism and insulin regulation, accumulating evidence suggests a more complex involvement in cellular processes that can influence cancer development and progression. Understanding this connection is crucial for advancements in cancer diagnostics and therapeutics.

Proinsulin, a precursor molecule, is processed in the pancreas to yield mature insulin and C-peptide. C-peptide, a 31-amino acid polypeptide, serves as a marker of endogenous insulin production. Historically, C-peptide has been recognized for its beneficial effects against diabetic complications, including preventing hyperglycemia-induced vascular leakage and metastasis of melanoma cells. Research by HY Jeon and colleagues in 2019 highlighted that C-peptide has a beneficial effect against diabetic complications, although its role in hyperglycemia-induced metastasis was initially less understood. Further investigations have indicated that proinsulin C-peptide can prevent hyperglycemia-induced vascular leakage and metastasis of melanoma cells in the lungs of diabetic mice. Moreover, studies suggest that C-peptide can enhance cell survival and protect against death signaling in myoblasts, as demonstrated by SM Essid and colleagues in 2019.

However, the landscape becomes more nuanced when considering the direct link between proinsulin peptide C and cancer. Several studies have explored the association between C-peptide levels and cancer risk. A meta-analysis by M Li and colleagues in 2020 suggested that C-peptide levels were positively related to breast cancer risk in women. Similarly, a prospective study by J Ma and colleagues in 2004 found a statistically significant association between increased plasma C-peptide concentration and an increased risk of colorectal cancer. Conversely, findings regarding pancreatic cancer have been mixed; a study from 2007 indicated that while fasting C-peptide and insulin were not related to pancreatic cancer, non-fasting C-peptide showed a strong linear association.

The mechanism by which proinsulin C-peptide might influence cancer is multifaceted. One area of investigation focuses on the impact of high glucose conditions. Research has shown that high glucose conditions can induce the migration and invasion of ovarian cancer cells, and human C-peptide has been observed to inhibit these metastatic processes, as reported by EB Kim and colleagues in 2024. This suggests a potential protective role in certain cancer types under specific metabolic conditions.

Another critical aspect involves the immune system. Proinsulin C-peptide has been identified as a major source of HLA-DQ8 restricted HIPs (human insulinoma-associated antigens) recognized by human islet-infiltrating CD4+ T cells. P Bhattacharjee and colleagues reported in 2024 that C-peptide, excised from proinsulin, has emerged as a major antigenic target of human islet-infiltrating and peripheral blood CD4+ T cells. Furthermore, proinsulin C-peptide is recognized by CD4+ T cells from individuals with recent onset Type 1 Diabetes (T1D), as shown by L Nordquist and colleagues in 2018. The proinsulin 33-63 -specific T-cell proliferation has also shown a positive association with concurrent estimated C-peptide and predicted survival in the honeymoon phase of T1D, according to Y Musthaffa and colleagues in 2021. This highlights the complex interplay between proinsulin, C-peptide, and immune responses, which could indirectly influence cancer immunity.

The proinsulin-to-C-peptide ratio (PI:C) is also a significant indicator. An elevated PI:C ratio can be indicative of beta-cell dysfunction. EK Sims and colleagues in 2023 found that for individuals with stage 2 type 1 diabetes, an elevated PI:C is highly indicative of impending progression to stage 3. This ratio can also be useful in identifying individuals at highest risk for beta-cell dysfunction and ultimately type 2 diabetes. In the context of tumors, particularly neuroendocrine tumors, elevated C-peptide and proinsulin with a high proinsulin to insulin ratio have been observed in diagnostic cases, as reported by K Ahmed in 2025. This suggests that proinsulin secreting neuroendocrine tumors can lead to altered levels of these peptides.

It is important to distinguish between the physiological roles of proinsulin peptide C and its potential pathological associations with cancer. While C-peptide itself is a crucial biomarker for pancreatic beta-cell function and has demonstrated protective effects in certain contexts, elevated levels or altered ratios of proinsulin and C-peptide could be associated with increased cancer risk or serve as indicators in specific tumor types.

In summary, the connection between proinsulin peptide C and cancer is complex and warrants further in-depth research. While C-peptide plays a vital role